Table 1:
Demographic and clinical characteristics of HDMTX treatment course in MTX cohort.
| Total (n = 189) | AKI (n = 35) | Non-AKI (n = 154) | P-value | |
|---|---|---|---|---|
| Age, years | 59.00 (51.00–65.00) | 59.00 (55.00–66.00) | 59.00 (50.25–65.00) | .259 |
| Male, n (%) | 128 (67.72) | 23 (65.71) | 105 (68.18) | .779 |
| BSA, m2 | 1.83 (1.70–1.89) | 1.85 (1.74–1.91) | 1.81 (1.70–1.89) | .437 |
| eGFR, mL/min/1.73 m2 | 98.13 (88.93–105.57) | 94.7 0(79.90–104.28) | 98.58 (89.46–105.59) | .158 |
| Hb, g/L | 125.95 ± 14.69 | 123.60 ± 15.29 | 126.49 ± 14.55 | .358 |
| WBC, ×109/L | 5.79 (4.50–7.34) | 5.77 (4.45–7.09) | 5.80 (4.50–7.45) | .923 |
| N% | 59.80 (52.55–67.45) | 62.20 (58.50–67.80) | 57.85 (51.90–67.32) | .355 |
| PLT, ×1012/L | 204.00 (162.50–249.00) | 187.00 (163.00–252.00) | 204.00 (161.00–249.00) | .816 |
| Diabetes, n (%) | 38 (20.10) | 15 (42.85) | 23 (14.93) | .006 |
| Hypertension, n (%) | 53 (28.04) | 14 (40.00) | 39 (25.32) | .134 |
| MTX dose, g/m2 | 4.56 (3.42–7.83) | 5.08 (3.49–7.83) | 4.13 (3.41–7.83) | .248 |
| Urine pH before MTX infusion | 7.50 (7.00–8.00) | 7.00 (7.00–8.00) | 7.50 (7.00–8.00) | .076 |
| Delayed MTX excretion, n (%) | 15 (7.93) | 12 (34.28) | 3 (1.94) | <.001 |
BSA, body surface area; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; WBC, white blood cell; N, neutrophil; PLT, platelet; MTX, methotrexate.